A team of researchers at the Perelman School of Medicine at the University of Pennsylvania has discovered that obese mice, treated with the cytokine (a category of proteins) known as TSLP, reported significant fat and weight loss. Described as an “unforeseen finding,” researchers also said that the fat loss was in no way related to decreased food intake or faster metabolism. The treatment revealed, “TSLP prompted the immune system to release lipids through the skin’s oil-producing sebaceous glands.”
The study is led by Taku Kambayashi, Associate Professor of Pathology and Laboratory Medicine at the University of Pennsylvania. He was joined by Ruth Choa, a fourth-year PhD medical student. Kambayashi said that despite being an unexpected discovery, the team has demonstrated that fat loss was possible by secreting calories from the skin in the form of energy-rich sebum. The professor added that the findings of the animal experiment also show that this could develop into a model for the treatment of obesity among people.
Kambayashi said that they never thought the TSLP would have any impact on obesity itself. What they set out for was to find out if it impacted insulin resistance. “We thought that the cytokine could correct Type 2 diabetes, without actually causing the mice to lose any weight,” he said.
In order to see the effect of TSLP on Type 2 diabetes, the researchers administered on obese mice a viral vector to increase their bodies’ TSLP levels. Four weeks after the mice were administered injections, the team found that TSLP, besides affecting their diabetes risk, also reduced obesity in them. Compared to TSLP-treated mice, the control group continued to gain weight. The TSLP-treated mice lost 20 grams, going from 45 to just 25 grams in 28 days, the team said.
Not just that, while the mice reported weight and fat loss, Kambayashi assumed that TSLP was perhaps sickening them. Upon further testing, the group realised that the mice receiving TSLP treatment were also eating 20 to 30 percent more. Besides, they also had similar energy expenditures, base metabolic rates, and activity levels compared to their non-treated counterparts.
Could this work on Humans?
The authors of the study said that in humans, shifting sebum release into “high gear” could feasibly lead to the “sweating of fat” and weight loss.
Kambayashi’s group next plans to test this hypothesis. He said that he doesn’t think humans naturally control their weight by regulating sebum production. “We may be able to hijack the process and increase sebum production to cause fat loss,” he said.
Aditya L1 Solar Mission Begins Studying Energetic Particles in Solar Wind
After India’s solar mission, Aditya L1 began its journey towards Lagrange point 1 following a key manoeuvre, it has started studying energetic particles in the solar wind from space and will continue to do so for the rest of its life, a senior astrophysicist said. The study of the solar wind, the continuous flow of charged particles from the sun which permeates the solar system, will be carried out with the help of a device named Supra Thermal & Energetic Particle Spectrometer (STEPS), a part of the Aditya Solar wind Particle Experiment (ASPEX) payload.
“STEPS is now working from space. However, it was not sitting idle earlier. It has started functioning from within the magnetic field of the Earth since September 10 when Aditya was 52,000 kilometres above our planet,” Dr Dibyendu Chakrabarty, professor of Space and Atmospheric Sciences at the Physical Research Laboratory (PRL) said.
STEPS was developed by the PRL with support from the Space Application Centre (SAC) in Ahmedabad.
“During the travel time of four months (till Aditya L1 reaches its destination), it will study energetic particles in the solar wind. The data will help maintain the health and performance of our space assets in a better way,” Dr Chakrabarty told PTI.
The key aim of STEPS is to study the environment of energetic particles from the spacecraft’s position on the L1 point till it will function, he said. “The data from STEPS in the long term will also help us understand how space weather changes,” the space scientist said.
STEPS comprises six sensors, each observing in different directions and measuring supra-thermal and energetic ions. The data collected during the Earth’s orbits helps scientists to analyse the behaviour of particles surrounding the planet, especially in the presence of its magnetic field.
Aditya-L1, launched by the Indian Space Research Organisation (ISRO) on September 2, will go up to the First Lagrangian point, about 1.5 million km from the Earth ISRO on September 18 said on X: “Off to Sun-Earth L1 point! The Trans-Lagrangean Point 1 Insertion (TL1I) manoeuvre is performed successfully. The spacecraft is now on a trajectory that will take it to the Sun-Earth L1 point.” Lagrangian points are where gravitational forces, acting between two objects, balance each other in such a way that the spacecraft can ‘hover’ for a longer period of time.
The L1 point is considered the most significant of the Lagrangian points, for solar observations, which were discovered by mathematician Joseph Louis Lagrange.
Elon Musk’s Neuralink Receives Approval to Start Brain Implant Human Trial
Billionaire entrepreneur Elon Musk‘s brain-chip startup Neuralink said on Tuesday it has received approval from an independent review board to begin recruitment for the first human trial of its brain implant for paralysis patients.
Those with paralysis due to cervical spinal cord injury or amyotrophic lateral sclerosis may qualify for the study, it said but did not reveal how many participants would be enrolled in the trial, which will take about six years to complete.
The study will use a robot to surgically place a brain-computer interface (BCI) implant in a region of the brain that controls the intention to move, Neuralink said, adding that its initial goal is to enable people to control a computer cursor or keyboard using their thoughts alone.
The company, which had earlier hoped to receive approval to implant its device in 10 patients, was negotiating a lower number of patients with the US Food and Drug Administration (FDA) after the agency raised safety concerns, according to current and former employees. It is not known how many patients the FDA ultimately approved.
Musk has grand ambitions for Neuralink, saying it would facilitate speedy surgical insertions of its chip devices to treat conditions like obesity, autism, depression and schizophrenia.
In May, the company said it had received clearance from the FDA for its first-in-human clinical trial when it was already under federal scrutiny for its handling of animal testing.
Even if the BCI device proves to be safe for human use, it would still potentially take more than a decade for the startup to secure commercial use clearance for it, according to experts.
© Thomson Reuters 2023
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
ISRO’s Aditya-L1 Performs TL1I Manoeuvre, Set to Reach Sun-Earth L1 Point
The Indian Space Research Organisation (ISRO) announced on Tuesday that its maiden solar mission — Aditya-L1 — has performed the Trans-Lagrangean Point 1 Insertion (TL1I) manoeuvre successfully and the spacecraft was now in a trajectory that will take it to the Sun-Earth L1 point. ISRO also informed that it marked the fifth consecutive time that the ISRO had successfully transferred an object on a trajectory toward another celestial body or location in space.
A post on the ISRO official handle on social media platform X read, “Aditya-L1 Mission | Off to Sun-Earth L1 point | The Trans-Lagrangean Point 1 Insertion (TL1I) manoeuvre is performed successfully. The spacecraft is now on a trajectory that will take it to the Sun-Earth L1 point. It will be injected into an orbit around L1 through a manoeuvre after about 110 days. This is the fifth consecutive time ISRO has successfully transferred an object on a trajectory toward another celestial body or location in space.”
Earlier, a launcher carrying the Aditya-L1 spacecraft blasted off from the Satish Dhawan Space Station at Sriharikota in Andhra Pradesh. The primary objectives of India’s maiden solar mission include collecting scientific data and marking another milestone in India’s solar exploration efforts.
The agency had earlier posted on X, “Aditya-L1 Mission: Aditya-L1 has commenced collecting scientific data. The sensors of the STEPS instrument have begun measuring supra-thermal and energetic ions and electrons at distances greater than 50,000 km from Earth. This data helps scientists analyze the behaviour of particles surrounding Earth. The figure displays variations in the energetic particle environment, collected by one of the units.”
The Supra Thermal and Energetic Particle Spectrometer (STEPS) instrument, a part of the Aditya Solar Wind Particle Experiment (ASPEX) payload, also started its data-gathering operations earlier.
Sports11 months ago
‘Storybook stuff’: Inside the night Bryce Harper sent the Phillies to the World Series
Environment4 months ago
Japan and South Korea have a lot at stake in a free and open South China Sea
Sports2 years ago
Team Europe easily wins 4th straight Laver Cup
Technology2 years ago
Game consoles were once banned in China. Now Chinese developers want a slice of the $49 billion pie
Sports6 months ago
MLB Rank 2023: Ranking baseball’s top 100 players
Environment7 months ago
Game-changing Lectric XPedition launched as affordable electric cargo bike
Politics2 years ago
Have the last few wobbly weeks seen a turning point for Johnson as PM?
Business12 months ago
Bank of England’s extraordinary response to government policy is almost unthinkable | Ed Conway